N-(5-substituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl) propanamides as glucokinase activators†
Abstract
A series of novel arylacetamides were designed to further explore the GK binding property at the aminothiazole C5 position. The C5-amide substituted aminothiazoles 7a–f generally displayed decreased potency, whereas most of the C5-triazole substituted aminothiazoles retained good GK potency.